AbbVie retains Humira market share above 70%: report

AbbVie (NYSE:ABBV) has managed to keep its market share for its bestselling arthritis therapy, Humira, above 70%, generic drugmaker Samsung Bioepis said in a new report on Thursday as the blockbuster marks its second anniversary of its U.S. biosimilar threat. 

The anti-inflammatory injection, also known as adalimumab, lost its U.S. market exclusivity in early 2023 after generating hundreds of billions of dollars in sales for AbbVie (NYSE:ABBV) since its first FDA approval in 2002.

After accounting for over a third of its revenue in 2022, Humira's contribution to AbbVie's (ABBV) topline plummeted to ~27% in 2023 as biosimilars from Amgen (AMGN), Teva (TEVA), and Pfizer (PFE) entered the market.

Despite retaining its dominance with a 96% market share as of February, Humira's market leadership came under threat in 2024, reaching 77% in May as large pharmacy benefit managers such as CVS Health (CVS) removed the branded version from major drug formularies.

However, according to Samsung Bioepis, ABBV continues to claim 72% of the adalimumab market in the U.S. as of November, even as its biosimilar threat has gained ground, claiming 23% of the market, up from 2% about a year ago.

The South Korean drugmaker added that Hyrimoz and Hadlima, Humira biosimilars marketed by CVS Health (CVS)/Sandoz (SDXNY) (OTCQX:SDZXF) and Organon (OGN)/Samsung Bioepis, respectively, have led to most of the gains.

Meanwhile, the contributions from other notable adalimumab makers, Amgen (AMGN), Teva (TEVA)/Alvotech (ALVO), and Pfizer (PFE), to the market stand at 3% or less, according to Samsung Bioepis.